Document is current

Article History

Received: 31 May 2024

Accepted: 6 November 2024

First Online: 18 December 2024

Declarations

:

: Melissa L. Johnson has received research grants to her institution from AbbVie, Adaptimmune, Amgen, Arcus Biosciences, Array BioPharma, ArriVent BioPharma, Artios Pharma, AstraZeneca, Bayer, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, City of Hope National Medical Center, Conjupro Biotherapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immuneering Corporation, Immunitas Therapeutics, Immunocore, Impact Therapeutics, Incyte, Janssen, Kartos Therapeutics, LockBody Therapeutics, Loxo Oncology, Memorial Sloan Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, NextPoint Therapeutics, Novartis, Numab Therapeutics, Nuvalent. OncoC4, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Summit Therapeutics, Syndax Pharmaceuticals, Systimmune, Taiho Oncology, Takeda Pharmaceuticals, TCR2 Therapeutics, Tempest Therapeutics, TheRas, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, Vividion, Vyriad, Y-mAbs Therapeutics; has received personal consulting/advising fees (all payments made to the institution) from AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, Arrivent, AstraZeneca, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio Limited, Daiichi Sankyo, Fate Therapeutics, Genentech/Roche, Genmab, Gilead Sciences, GlaxoSmithKline, Gritstone Oncology, Hookipa Biotech, Immunocore, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, ModeX Therapeutics, Molecular Axiom, Normunity, Novartis, Novocure, Pfizer, Pyramid Biosciences, Revolution Medicines, Sanofi-Aventis, Seagen, Synthekine, Takeda Pharmaceuticals, Zai Laboratory. Jessica J. Lin has received institutional research funding from Hengrui Therapeutics, Turning Point Therapeutics, Novartis, Neon Therapeutics, Bayer, Roche/Genentech, Pfizer, Elevation Oncology, Relay Therapeutics, Linnaeus Therapeutics, Nuvalent; has received personal honorarium/consulting/ad board fees from Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, Regeneron, Pfizer, Takeda, Ellipses Pharma, Hyku BioSciences, AnHeart Therapeutics, Claim Therapeutics, Merus, Bristol Myers Squibb, Daiichi Sankyo, AstraZeneca, Yuhan, and Turning Point Therapeutics. Adrienne Boire has received a grant from NCI Cancer Center; has received personal consulting fees from Apelis Pharmaceuticals; has received travel support from the Geoffrey Beene Foundation; has a patent (institution holds license [International Patent Application No. PCT/US24/18343, US patent application no. 63/449,817, and 63/449,823]). Melin J. Khandekar has nothing to disclose. Helena A. Yu has received research funding to her institution from AstraZeneca, Novartis, Pfizer, Daiichi Sankyo, Cullinan Oncology, Janssen Oncology, Erasca, Inc, Blueprint Medicines, Black Diamond, Systimmune; has received personal consulting fees from AstraZeneca, Daiichi Sankyo, Cullinan, Janssen, Blueprint, Black Diamond, Amgen, Takeda, Taiho.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.